New diabetes pill shows promise in Real-World finnish study
NCT ID NCT05443191
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study followed 50 adults with type 2 diabetes in Finland who were prescribed oral semaglutide (Rybelsus) by their doctor. The goal was to see how well the medication lowers blood sugar levels over 8-10 months. Participants completed a questionnaire about how they took their tablets during a regular clinic visit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aava Lääkärikeskus Kamppi
Helsinki, 00100, Finland
-
Master Centre for Finland
Helsinki, Finland, 00100, Finland
-
Master centre for France_Paris La défense cedex
Paris, La Défense, cedex, France
Conditions
Explore the condition pages connected to this study.